Overview
ABT market data
Price History
ABT price chart
Valuation & Profitability
- P/E (TTM)
- 32.33 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $3.73 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.58 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 250.3% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $81.97 – $137.49 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $175.4K · P/B 4.18 · P/S 3.76.
Company news
Blood Transfusion Diagnostics Market Size to Hit USD 8.67 Billion by 2035 as Automated Testing and AI-Driven Blood Safety Solutions Accelerate Growth | SNS InsiderGlobenewswire Inc · Jul 24, 2026, 2:15 PM
Citigroup Maintains Buy on Abbott Laboratories, Raises Price Target to $112Benzinga · Jul 17, 2026, 6:22 PM
Piper Sandler Reiterates Overweight on Abbott Laboratories, Raises Price Target to $118Benzinga · Jul 17, 2026, 6:09 PM
JP Morgan Maintains Overweight on Abbott Laboratories, Raises Price Target to $120Benzinga · Jul 17, 2026, 2:56 PM
Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $112Benzinga · Jul 17, 2026, 2:28 PM
Abbott Laboratories shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $131 to $134. Also, Evercore ISI Group maintained its Outperform rating and raised its price target from $112 to $120.Benzinga · Jul 17, 2026, 2:27 PM
TD Cowen Reiterates Buy on Abbott Laboratories, Maintains $115 Price TargetBenzinga · Jul 17, 2026, 2:00 PM
These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 ResultsBenzinga · Jul 17, 2026, 1:38 PM
Evercore ISI Group Maintains Outperform on Abbott Laboratories, Raises Price Target to $120Benzinga · Jul 17, 2026, 1:34 PM
RBC Capital Reiterates Outperform on Abbott Laboratories, Maintains $130 Price TargetBenzinga · Jul 17, 2026, 1:02 PM